Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data

Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K AntagonistsCLINICAL PERSPECTIVES

(2015) Géric Maura et al.   CIRCULATION

Validity ofInternational Classification of DiseaseCodes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation

(2015) Jonathan L. Thigpen et al.  

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure

(2015) Colleen A. McHorney et al.   CURRENT MEDICAL RESEARCH AND OPINION

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

(2015) Paul A. Reilly et al.   THROMBOSIS AND HAEMOSTASIS

Validity ofInternational Classification of DiseaseCodes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation

(2015) Jonathan L. Thigpen et al.   Circulation-Cardiovascular Quality and Outcomes

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

(2015) H.-Y. Chang et al.   BMJ-British Medical Journal

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

(2015) H.-Y. Chang et al.   BMJ-British Medical Journal

One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation

(2015) Marta A. Miyares   JAMA Internal Medicine

Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation

(2015) Siyao Liu et al.   JAMA Internal Medicine

Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data

(2015) Inmaculada Hernandez et al.   JAMA Internal Medicine

Risk of Bleeding With Dabigatran in Atrial Fibrillation

(2015) Inmaculada Hernandez et al.   JAMA Internal Medicine

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients

(2014) François Laliberté et al.   CURRENT MEDICAL RESEARCH AND OPINION

Risk of Gastrointestinal Bleeding with Dabigatran: A Head-to-Head Comparative Study with Rivaroxaban

(2014) Muhammed Sherid et al.   DIGESTION

Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban

(2013) A. FAWOLE et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation

(2013) Torben Bjerregaard Larsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Factors Associated With Major Bleeding Events

(2013) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score

(2013) Daniel E. Singer et al.   Journal of the American Heart Association

Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation

(2012) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

(2012) Jack Ansell et al.   THROMBOSIS AND HAEMOSTASIS

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elderly Women Have Lower Rates of Stroke, Cardiovascular Events, and Mortality After Hospitalization for Transient Ischemic Attack

(2009) Judith H. Lichtman et al.   STROKE